SECURITIES GOVERNANCE | 2026-02-27
SEC and DOJ Insider Trading Enforcement in Life Sciences and Biotech: California Analysis 2026
Analyzing the coordinated SEC and DOJ enforcement wave targeting insider trading in life sciences and biopharmaceutical companies, including the Wang, Suthoff, and Emergent BioSolutions actions, and implications for California biotech corridor companies and executives in 2026
By Anatolii Trembach, Esq. (California State Bar No. 349304; LL.M., USC Gould School of Law; admitted to the U.S. Court of International Trade), Trembach Law Firm, APC · Published
The opening weeks of 2026 have delivered a decisive signal to the life sciences and biopharmaceutical industries: the Securities and Exchange Commission and the Department of Justice are pursuing insider trading enforcement with renewed intensity and sophisticated coordination. In January 2026 alone, federal and state regulators announced a series of enforcement actions that collectively span the full spectrum of insider trading theories.
Contact Trembach Law Firm at (818) 514-7680 for a confidential consultation.
Trembach Law Firm | 27001 Agoura Road, Suite 350, Calabasas, CA 91301